Pharmos’ dexanabinol (correction)
Pharmos' Phase III trial for its cannabinoid dexanabinal in traumatic brain injury has completed projected enrollment of about 860 patients in the U.S. and other countries; results are expected by year-end. FDA placed the NMDA antagonist on fast track status in September 2003. Dexanabinol has never been in clinical development for Parkinson's disease or Alzheimer's disease as suggested in the 1March 22 issue of "The Pink Sheet" (p. 38)...
You may also be interested in...
Novartis' and Cephalon's disease-modifying Parkinson's disease agents are approaching the final stages of development, with at least one pivotal trial slated to begin in 2004
If J&J’s gamble on a single dose pays off, it could rapidly advance the fight against SARS-CoV2 – but a second study will provide a safety net.
Agency has been prepping Woodcock for the temporary task but what will happen to her role on Operation Warp Speed remains unclear. The move should give Biden team cushion to confirm a permanent leader of whom a top contender is former senior FDA staffer Joshua Sharfstein, a proponent of drug reforms that may irk manufacturers.